Clinical Trials Logo

Filter by:
NCT ID: NCT01399684 Completed - Clinical trials for Metastatic Colorectal Cancer

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Start date: November 2011
Phase: Phase 2
Study type: Interventional

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to estimate the efficacy of MEGF0444A treatment to disease progression, combined with oxaliplatin + folinic acid + 5-Fluorouracil (mFOLFOX-6) + bevacizumab therapy in participants with metastatic colorectal cancer (CRC).

NCT ID: NCT01398384 Completed - Clinical trials for Acute Myocardial Infarction

Effects of Nitric Oxide for Inhalation in Myocardial Infarction Size

NOMI
Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of Nitric Oxide for Inhalation on Myocardial Infarction Size.

NCT ID: NCT01398111 Completed - COPD Clinical Trials

Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers

TRIPLE 1
Start date: May 2011
Phase: Phase 1
Study type: Interventional

This study will be carried out in healthy volunteers with the primary objective to evaluate the pharmacokinetic interaction between Glyco and Formoterol administered using a pressurised metered dose inhaler (pMDI).

NCT ID: NCT01397396 Completed - COPD Clinical Trials

Effects of Inspiratory Muscle Training in COPD

IMTCO
Start date: February 2012
Phase: Phase 3
Study type: Interventional

The additional effect of inspiratory muscle training as an adjunct to a general exercise training program in patients with COPD with inspiratory muscle weakness will be studied. The main hypothesis is that inspiratory muscle training combined with an exercise training program improves functional exercise capacity more than an exercise training program without the addition of an inspiratory muscle training program.

NCT ID: NCT01396798 Completed - Sepsis Clinical Trials

Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E.

ERNIE3
Start date: February 2011
Phase: N/A
Study type: Observational

Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Acutely Ill Children in a High Prevalent Setting: The Paediatric Accidents & Emergencies through prospective observational data collection concerning specific items from the clinical and technical examination in diagnosing serious infections, such as meningitis, sepsis, pneumonia, pyelonephritis, bronchiolitis with hypoxia. Eventually we will attempt to validate a vital signs and symptoms rule derived from multiple low to high prevalent settings of acutely ill children.

NCT ID: NCT01395914 Completed - Clinical trials for Non-Small Cell Lung Cancer

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Start date: July 2011
Phase: Phase 3
Study type: Interventional

The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.

NCT ID: NCT01395017 Completed - Pancreatic Cancer Clinical Trials

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

LAPC
Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.

NCT ID: NCT01393652 Completed - Healthy Volunteers Clinical Trials

Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679

SINGLE DOSE
Start date: May 2011
Phase: Phase 1
Study type: Interventional

This is a two part study. The purpose of the first part (Part A) is the evaluation of the pharmacokinetics, safety and tolerability after single ascending dose of PF-05105679. The second part (Part B) of this study will focus on the exploratory pharmacodynamics of PF-05105679 using pharmacodynamics markers (cold detection) in healthy volunteers. The doses selected in Part B will have been administered previously in the Part A of the study.

NCT ID: NCT01393340 Completed - Asthma Clinical Trials

Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This pilot study is a double-blinded, randomized controlled, two-centre trial in which subjects will receive 4 to 8 (subcutaneous administered) doses of medication (Omalizumab or placebo) (dose and dosing interval calculated on body weight and baseline total serum IgE). During the treatment period and follow-up, the clinical efficacy of the treatment will be assessed by evaluation of symptoms, Quality of Life questionnaire, morning Peak Expiratory Flow measurement, smell test, nasal endoscopy, CT-scan, peak nasal inspiratory flow and spirometry. Biological activity will be evaluated by measuring peripheral and local (in serum, in nasal secretions, biopsies) markers of inflammation. Study hypothesis 1. Evaluation of the efficacy and safety of anti-IgE (Omalizumab) in patients with nasal polyposis and comorbid asthma. 2. Exploration of anti-IgE effects on local and systemic metabolism of IgE in nasal polyposis 3. Clinical assessment of the IgE theory in the pathogenesis of nasal polyps

NCT ID: NCT01392469 Completed - Clinical trials for Pulmonary Arterial Hypertension

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

Start date: April 20, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.